<DOC>
	<DOCNO>NCT01163266</DOCNO>
	<brief_summary>The purpose study evaluate efficacy vortioxetine , daily ( QD ) , compare placebo adult major depressive disorder .</brief_summary>
	<brief_title>Efficacy Safety Study Vortioxetine ( Lu AA21004 ) Adults With Major Depressive Disorder</brief_title>
	<detailed_description>The drug test study call Vortioxetine . Vortioxetine test treat depression adult major depressive disorder ( MDD ) . This study look MDD relief people take vary dosage vortioxetine . The study enrol 462 patient . Participants randomly assign ( chance , like flip coin ) one three treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Vortioxetine 10 mg - Vortioxetine 20 mg - Placebo ( dummy inactive capsule ) - capsule look like study drug active ingredient . All participant ask take one capsule time day throughout study . This multi-center trial conduct United States . The overall time participate study 13 week . Participants make 9 visit clinic , contact telephone 4 week last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>Suffers major depressive episode recurrent primary diagnosis accord American Psychiatric Association Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criterion . Has Montgomery Åsberg Depression Rating Scale ( MADRS ) total score 26 great Screening Baseline Visits . Has Clinical Global Impression Severity Illness ( CGIS ) score 4 great Screening Baseline Visits . Has previously participate Lu AA21004 clinical study . Has 1 follow : Any current psychiatric disorder Major Depressive Disorder define DSMIV Current past history : manic hypomanic episode , schizophrenia psychotic disorder define DSMIVTR . Diagnosis alcohol substance disorder ( except nicotine caffeine ) define DSMIVTR sustain full remission least year prior screen ( participant must also negative urine drug screen prior Baseline ) . Presence history clinically significant neurological disorder ( include epilepsy ) Neurodegenerative disorder . Any Axis II disorder might compromise study . Has thyroid stimulate hormone value outside normal range Screening Visit deem clinically significant investigator . Has clinically significant abnormal vital sign determine investigator . Has abnormal Electrocardiogram . Has alanine aminotransferase , aspartate aminotransferase total bilirubin level great 1.5 time upper limit normal . Has previous history cancer remission le 5 year prior first dose study medication . Has disease take medication , opinion investigator , could interfere assessment safety , tolerability , efficacy . Has know history currently increase intraocular pressure risk acute narrowangle glaucoma . Has clinically significant unstable illness , example , hepatic impairment renal insufficiency , cardiovascular , pulmonary , gastrointestinal , endocrine , neurological , rheumatologic , immunologic , infectious , skin subcutaneous tissue disorder , metabolic disturbance . For purpose protocol follow condition consider unstable due potential impact assessment MDD response : pain disorder , chronic fatigue syndrome , fibromyalgia , obstructive sleep apnea . Has significant risk suicide accord investigator 's opinion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Melancholia</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>